



## MAYNE PHARMA ANNOUNCES PBS LISTING OF NEXTSTELLIS® IN AUSTRALIA

### Key Points:

- The Pharmaceutical Benefits Scheme (PBS) has approved the reimbursement of Mayne Pharma's oral contraceptive NEXTSTELLIS®.
- First and only approved contraceptive pill containing estetrol (E4), a natural estrogen produced by the human body during pregnancy, now derived from a plant source.

**29 September 2025, Adelaide, Australia:** Mayne Pharma Group Limited (Mayne Pharma) (ASX: MYX), is pleased to announce the Australian Pharmaceutical Benefits Scheme (PBS) has approved the reimbursement of oral contraceptive NEXTSTELLIS®. From 1 October 2025, NEXTSTELLIS® will be listed on the PBS General Schedule.

**Shawn Patrick O'Brien, CEO and Managing Director, Mayne Pharma said** "We are pleased with the PBS listing of NEXTSTELLIS®. The expansion of contraceptive options available on the PBS in Australia aligns with Mayne Pharma's commitment to provide better, safe and more accessible medicines. The listing of NEXTSTELLIS® on the PBS provides healthcare professionals a broader range of safe and effective reproductive health therapies for their female patients."

NEXTSTELLIS® was approved by the Australian Therapeutic Goods Administration (TGA) in November 2021 and is the first and only approved contraceptive pill containing estetrol (E4), and a progestin, namely drospirenone. E4 is a natural estrogen produced by the human body during pregnancy and in NEXTSTELLIS®, E4 is derived from a plant source to match the body's naturally occurring E4<sup>1</sup>.

In 2023 the report of the Senate Community Affairs References Committee inquiry into universal access to reproductive healthcare was published. A recommendation was made to improve access to a broader range of hormonal contraceptives, including newer forms of the oral contraceptive pill subsidised through the PBS.<sup>2</sup> NEXTSTELLIS® is one these newer contraceptives and marks another positive step toward better healthcare for women.

Around 1.7 million Australian women of reproductive age use some form of contraception every year. In 2024, around 520,000 patients accessed a comparable oral contraception.

Without listing on the PBS NEXTSTELLIS® would cost more than \$328 per year. Women will now be able to access NEXTSTELLIS® at \$31.60 for 3 months supply for general patients (reducing to \$25 from 1 January 2026). Concession card holders will be able to access NEXTSTELLIS® for \$7.70 for 3 months supply.

<sup>1</sup> NEXTSTELLIS® Product Information

<sup>2</sup>

[https://www.aph.gov.au/Parliamentary\\_Business/Committees/Senate/Community\\_Affairs/Reproductive\\_Healthcare/Report/Chapter\\_2\\_-\\_Enhancing\\_access\\_to\\_contraceptives](https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Reproductive_Healthcare/Report/Chapter_2_-_Enhancing_access_to_contraceptives)

For personal use only



- ENDS -

For further information contact:

Dr Tom Duthy  
Investor Relations  
+61 402 493 727  
[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Board Chair.

#### **About Mayne Pharma**

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).

NEXTSTELLIS® is a trademark of a third party.

For personal use only

